Functional MRI of basal ganglia responsiveness to levodopa in Parkinsonian rhesus monkeys

Experimental Neurology

Volumn 158, Issue 1, 1999, Pages 63-75

  Chen, Qun ^a   Andersen, Anders H ^a   Zhang, Zhiming ^a   Ovadia, Aliza ^a   Cass, Wayne A ^a   Gash, Don M ^a   Avison, Malcolm J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; DOSE TIME EFFECT RELATION; FEMALE; IMAGE ANALYSIS; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RHESUS MONKEY; TREATMENT OUTCOME;

EID: 0032818792     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7089     Document Type: Article

References (74)

1. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv. Neurol. 60:1993;140-147.
2. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45:1987;1-18.
3. Muenter M. D., Tyce G. M. L-DOPA therapy in Parkinson's disease: Plasma L-DOPA concentration, therapeutic response and side effects. Mayo Clin. Proc. 46:1971;231-239.
4. Nutt J. G. Levodopa-induced dyskinesia. Neurology. 40:1990;340-345.
5. Blanchette P., Bedard P. J., Matsumura M., Richard H., Filion M. Pathophysiology of levodopa-induced dyskinesia: Changing concepts. Perceron G. The Basal Ganglia. 1994;539-548 Plenum.
6. Ogawa S., Lee T.-M., Kay A. R., Tank D. W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. USA. 87:1990;9868-9872.
7. Ogawa S., Tank D. W., Menon R., Ellermann J. M., Kim S. G., Merkle H., Ugurbil K. Intrinsic signal changes accompanying sensory stimulation: Functional brain mapping with magnetic resonance imaging. Proc. Natl. Acad. Sci. USA. 89:1992;5951-5955.
8. Chen Q., Andersen A. H., Zhang Z., Ovadia A., Gash D. M., Avison M. J. Mapping drug-induced changes in cerebral R2* by multiple gradient recalled echo functional MRI. Magn. Reson. Imag. 14:1995;469-476.
9. Chen Y. C., Galpern W. R., Brownell A. L., Matthews R. T., Bogdanov M., Isacson O., Keltner J. R., Beal M. F., Rosen B. R., Jenkins B. G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 38:1997;389-398.
10. Gyngell M. L., Bock C., Schmitz B., Hoehn Berlage M., Hossmann K. A. Variation of functional MRI signal in response to frequency of somatosensory stimulation in alpha-chloralose anesthetized rats. Magn. Reson. Med. 36:1996;13-15.
11. Hyder F., Behar K. L., Martin M. A., Blamire A. M., Shulman R. G. Dynamic magnetic resonance imaging of the rat brain during forepaw stimulation. J. Cereb. Blood Flow Metab. 14:1994;649-655.
12. Trugman J. M., Wooten G. F. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J. Neurosci. 7:1987;2927-2935.
13. Wooten G. F., Collins R. C. Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions. Brain Res. 263:1983;267-275.
14. Mitchell I. J., Boyce S., Sambrook M. A., Crossman A. R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain. 115:1992;809-824.
15. Pontieri F. E., Viola J. J., Sokoloff L., Porrino L. J. Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys. NeuroReport. 6:1995;1330-1332.
16. Porrino L. J., Burns R. S., Crane A. M., Palombo E., Kopin I. J., Sokoloff L. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Proc. Natl. Acad. Sci. USA. 84:1987;5995-5999.
17. Gagnon C., Bedard P. J., Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur. J. Pharmacol. 178:1990;115-120.
18. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J. Jr., Sibley D. R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons [see comments]. Science. 250:1990;1429-1432.
19. Graham W. C., Sambrook M. A., Crossman A. R. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 602:1993;290-303.
20. Morissette M., Goulet M., Calon F., Falardeau P., Blanchet P. J., Bedard P. J., Di Paolo T. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol. Pharmacol. 50:1996;1073-1079.
21. Abercrombie E. D., Bonatz A. E., Zigmond M. J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525:1990;36-44.
22. Bankiewicz K., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., Kopin I. J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:1986;7-16.
23. Smith R. D., Zhang Z., Kurlan R., McDermott M., Gash D. M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience. 52:1993;7-16.
24. Ovadia A., Zhang Z., Gash D. M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging. 16:1995;931-937.
25. Saunders R. C., Aigner T. G., Frank J. A. Magnetic resonance imaging of the rhesus monkey brain: Use of stereotactic neurosurgery. Exp. Brain Res. 81:1990;443-446.
26. Collin A. K., Stahle L., Ungerstedt U. Effects of halothane anesthesia on extracellular levels of DA, DOPAC, HVA and 5HIAA in the rat striatum: A microdialysis study. Acta Physiol. Scand. 132:1988;30.
27. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P. A., Collins F., Hilt D., Lebel C., Kryscio R., Gash D. M. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. 42:1997;208-214.
28. Robinson T. E., Wishaw I. Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
29. Fox P. T., Raichle M. E. Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc. Natl. Acad. Sci. USA. 83:1986;1140-1144.
30. Black K. J., Gado M. H., Perlmutter J. S. PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function. J. Neurosci. 17:1997;3168-3177.
31. Sharkey J., McBean D. E., Kelly P. A. Acute cocaine administration: Effects on local cerebral blood flow and metabolic demand in the rat. Brain Res. 548:1991;310-314.
32. Berntman L., Carlsson C., Hagerdal M., Siesjo B. K. Excessive increase in oxygen uptake and blood flow in the brain during amphetamine intoxication. Acta Physiol. Scand. 97:1976;264-266.
33. Berntman L., Carlsson C., Hagerdal M., Siesjo B. K. Circulatory and metabolic effects in the brain induced by amphetamine sulphate. Acta Physiol. Scand. 102:1978;310-323.
34. McCulloch J., Harper A. M. Cerebral circulation: Effect of stimulation and blockade of dopamine receptors. Am. J. Physiol. 233:1977;H222-H227.
35. McCulloch J., Kelly P. A., Ford I. Effect of apomorphine on the relationship between local cerebral glucose utilization and local cerebral blood flow (with an appendix on its statistical analysis). J. Cereb. Blood Flow Metab. 2:1982;487-499.
36. McCulloch J., Edvinsson L. Cerebral circulatory and metabolic effects of piribedil. Eur. J. Pharmacol. 66:1980;327-337.
37. Ingvar M., Lindvall O., Stenevi U. Apomorphine-induced changes in local cerebral blood flow in normal rats and after lesions of the dopaminergic nigrostriatal bundle. Brain Res. 262:1983;259-265.
38. Leenders K. L., Wolfson L., Gibbs J. M., Wise R. J., Causon R., Jones T., Legg N. J. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain. 108:1985;171-191.
39. Sabatini U., Rascol O., Celsis P., Houin G., Rascol A., Marc Vergnes J. P., Montastruc J. L. Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms. Br. J. Clin. Pharmacol. 32:1991;229-234.
40. Tuor U. I., Edvinsson L., McCulloch J. Catecholamines and the relationship between cerebral blood flow and glucose use. Am. J. Physiol. 251:1986;H824-H833.
41. Kobari M., Fukuuchi Y., Shinohara T., Nogawa S., Takahashi K. Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy: Comparison with Parkinson's disease. Arch. Neurol. 49:1992;725-730.
42. Trugman J. M., Wooten G. F. The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res. 379:1986;264-274.
43. Ervin G. N., Fink J. S., Young R. C., Smith G. P. Different behavioral responses to L-DOPA after anterolateral or posterolateral hypothalamic injections of 6-hydroxydopamine. Brain Res. 132:1977;507-520.
44. Hefti F., Melamed E., Sahakian B. J., Wurtman R. J. Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA. Pharmacol. Biochem. Behav. 12:1980;185-188.
45. Hollister A. S., Breese G. R., Mueller R. A. Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J. Pharmacol. Exp. Ther. 208:1979;37-43.
46. Porrino L. J., Burns R. S., Crane A. M., Palombo E., Kopin I. J., Sokoloff L. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate. Life Sci. 40:1987;1657-1664.
47. Rougemont D., Baron J. C., Collard P., Bustany P., Comar D., Agid Y. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 47:1984;824-830.
48. Perlmutter J. S., Raichle M. E. Regional blood flow in hemiparkinsonism. Neurology. 35:1985;1127-1134.
49. Alexander G. M., Schwartzman R. J., Grothusen J. R., Brainard L., Gordon S. W. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res. 625:1993;276-282.
50. Falardeau P., Bedard P. J., Di Paolo T. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys. Neurosci. Lett. 86:1988;225-229.
51. Mata M., Fink D. J., Gainer H., Smith C. B., Davidsen L., Savaki H., Schwartz W. J., Sokoloff L. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J. Neurochem. 34:1980;213-215.
52. Schwartz W. J., Smith C. B., Davidsen L., Savaki H., Sokoloff L., Mata M., Fink D. J., Gainer H. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science. 205:1979;723-725.
53. Villringer A., Dirnagl U. Coupling of brain activity and cerebral blood flow: Basis of functional neuroimaging. Cerebrovasc. Brain Metab. Rev. 7:1995;240-276.
54. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed. Proc. 40:1981;2311-2316.
55. Chen A. J.-W., Chen Y.-C. I., Nguyen V., Keltner J. R., Rosen B. R., Jenkins B. G. Pharmacologic dissection of presynaptic and postsynaptic contributions to neurovascular coupling in functional magnetic resonance imaging. International Society for Magnetic Resonance in Medicine. 1998;. p. 2196.
56. Blanchet P. J., Calon F., Martel J. C., Bedard P. J., DiPaulo T., Walter R. R., Piercey M. F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP monkeys. J. Pharmacol. Exp. Ther. 272:1995;854-859.
57. Falardeau P., Bouchard S., Bedard P. J., Boucher R., DiPaulo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP-monkeys. Eur. J. Pharmacol. 150:1988;59-66.
58. Calon F., Goulet M., Blanchet P., Martel J.-C., Piercy M. F., Bedard P. J., DiPaolo T. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: Correlation with changes in dopamine and GABA-A receptors in the striatopallidal complex. Brain Res. 680:1994;43-52.
59. Todd R. D., Carl J., Harmon S., O'Malley K. L., Perlmutter J. S. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J. Neurosci. 16:1996;7776-7782.
60. Graham W. C., Clarke C. E., Boyce S., Sambrook M. A., Crossman A. R., Woodruff G. N. Autoradiographic studies in animal models of hemiparkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intracarotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 514:1990;103-110.
61. Alexander G. M., Brainard L., Gordon S. W., Hichens M., Grothusen J. R., Schwartzman R. J. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates. Brain Res. 547:1991;181-189.
62. Skirboll S., Wang J., Mefford I., Hsiao J., Bankiewicz K. S. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp. Neurol. 110:1990;187-193.
63. Cass W. A., Zahniser N. R., Flach K. A., Gerhardt G. A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: Role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61:1993;2269-2278.
64. Cass W. A., Gerhardt G. A., Zhang Z., Ovadia A., Gash D. M. Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions. Neurosci. Lett. 185:1995;52-55.
65. Horn A. S. Characteristics of dopamine uptake. Horn A. S., Korf J., Westerink B. H. C. The Neurobiology of Dopamine. 1979;217-235 Academic Press.
66. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
67. Pearce R. K., Jackson M., Smith L., Jenner P., Marsden C. D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10:1995;731-740.
68. Joyce J. N., Marshall J. F., Bankiewicz K. S., Kopin I. J., Jacobowitz D. M. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res. 382:1986;360-364.
69. Selemon L. D., Goldman-Rakic P. S. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J. Neurosci. 5:1985;776-794.
70. Flaherty A. W., Graybiel A. M. Corticostriatal transformations in the primate somatosensory system: Projections from physiologically mapped body-part representations. J. Neurophysiol. 66:1991;1249-1263.
71. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience. 44:1991;591-605.
72. Braak H., Braak E., Yilmazer D., de V. R., Jansen E. N., Bohl J., Jellinger K. Amygdala pathology in Parkinson's disease. Acta Neuropathol. (Berl.). 88:1994;493-500.
73. Bjorklund A., Lindvall O. Bjorklund A., Hokfelt T. Handbook of Chemical Neuroanatomy. 1984;55-122 Elsevier, Amsterdam.
74. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev. Neurosci. 5:1994;27-41.